Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus plus low-dose pirfenidone for idiopathic inflammatory myopathy-associated interstitial lung disease
ChiCTR2100044854Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus and pirfenidone in Autoimmune Myopathies and interstitial lung disease (ILD) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Pulmonary function parameters, All-cause mortality and 4 more. Started Apr 2021; status: recruiting.
02
Drugs
tacrolimuspirfenidone
03
Conditions
Autoimmune Myopathiesinterstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR2100044854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044854.